Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

motherlandreturns Jan. 13 at 8:21 PM

$ATHE have they been mentioned or anything at the JP Morgan conference?

1 · Reply

stckmuncher Jan. 13 at 1:04 AM

$ATHE What day and time are they presenting?

1 · Reply

RocketMan88 Jan. 12 at 1:07 PM

$ATHE is this the week we go back above 4 inches/dollars?

0 · Reply

stckmuncher Jan. 12 at 10:19 AM

$ATHE Put your seatbelt on folks, its about to get WILD!

0 · Reply

motherlandreturns Jan. 10 at 1:32 AM

$ATHE Yes 🙌

0 · Reply

stckmuncher Jan. 9 at 11:45 PM

$ATHE BLOWING LOADS 🤑

0 · Reply

Dingo2 Jan. 9 at 3:20 PM

$ATHE well, would be nice if this is the sleeper stock of 2026 that pulls off huge surprise... 😉

1 · Reply

GA09 Jan. 9 at 1:49 PM

$ATHE CEO is at JPM Conference. Could come out with either a partnership structure or an outright acquisition.

1 · Reply

tommy_john Jan. 9 at 12:55 PM

$ATHE slowly grinding up again. Show me $3.50-4

1 · Reply

stckmuncher Jan. 9 at 12:25 AM

$ATHE CAME CLOSE TO BLOWING MY LOAD TODAY!!!

0 · Reply

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Oct 31, 2025, 7:25 AM EDT - 2 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 9, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 3 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Sep 8, 2025, 7:35 AM EDT - 4 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 2, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics to Present at the Biotech Showcase

Jul 30, 2025, 7:25 AM EDT - 6 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 28, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 24, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jun 23, 2025, 7:25 AM EDT - 7 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 8 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 9 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 9 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 10 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 2 years ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 2 years ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Nov 27, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

motherlandreturns Jan. 13 at 8:21 PM

$ATHE have they been mentioned or anything at the JP Morgan conference?

1 · Reply

stckmuncher Jan. 13 at 1:04 AM

$ATHE What day and time are they presenting?

1 · Reply

RocketMan88 Jan. 12 at 1:07 PM

$ATHE is this the week we go back above 4 inches/dollars?

0 · Reply

stckmuncher Jan. 12 at 10:19 AM

$ATHE Put your seatbelt on folks, its about to get WILD!

0 · Reply

motherlandreturns Jan. 10 at 1:32 AM

$ATHE Yes 🙌

0 · Reply

stckmuncher Jan. 9 at 11:45 PM

$ATHE BLOWING LOADS 🤑

0 · Reply

Dingo2 Jan. 9 at 3:20 PM

$ATHE well, would be nice if this is the sleeper stock of 2026 that pulls off huge surprise... 😉

1 · Reply

GA09 Jan. 9 at 1:49 PM

$ATHE CEO is at JPM Conference. Could come out with either a partnership structure or an outright acquisition.

1 · Reply

tommy_john Jan. 9 at 12:55 PM

$ATHE slowly grinding up again. Show me $3.50-4

1 · Reply

stckmuncher Jan. 9 at 12:25 AM

$ATHE CAME CLOSE TO BLOWING MY LOAD TODAY!!!

0 · Reply

GA09 Jan. 6 at 10:57 PM

$ATHE May see movement (to the upside) after presentation at JPM Conference. Opportunity for partnership or acquisition.

0 · Reply

ButcherBillCutting Jan. 2 at 4:07 PM

$ATHE 1st update for ‘26 is in 10 days or so Cheers if you added under $3 in Dec.🧠

1 · Reply

SuperGreenToday Dec. 29 at 10:57 AM

$ATHE

0 · Reply

BronzeBolt Dec. 27 at 12:50 PM

$ATHE Momentum remains fragile and reacts quickly to operational clarity; cost controls have to translate into healthier margins — clear evidence of repeatability would change the narrative. Until validation appears, volatility remains the default.

0 · Reply

SpoofingS Dec. 27 at 5:52 AM

$ATHE Expectations are resetting toward sustainable results, not one‑off wins. Execution risk remains the main variable to watch. Execution consistency is the fastest path to confidence rebuilding. Future returns depend more on reliability than ambition.

0 · Reply

AshleySchaeffer_BMW Dec. 25 at 4:29 PM

$ATHE Merry Christmas to the fATHEful true believers!

0 · Reply

ButcherBillCutting Dec. 24 at 4:33 PM

$ATHE Patience and Merry Christmas Dr. Stamler will provide Ignore the BOTs

0 · Reply

YGLD Dec. 22 at 11:46 AM

You’re Not As Hungry As You Claim To Be 🤨 $AMCI $ATHE $AZI $LAZR $PCSA

1 · Reply

YGLD Dec. 22 at 11:13 AM

Your Greatest Trading Mistakes Will Come From Your Ego - $AMCI $ATHE $AZI $LAZR $PCSA

1 · Reply

MR_Good_Er00r Dec. 22 at 5:27 AM

$AMCI $ATHE $LAZR $SPY $WTI @YGLD jfc you should start A channel called 'snapshots n stonks' or Something feed us all the juicy snippets Of actual fun and interesting media then Talk your picks pack it in 15 Minutes Each episode hit the YT rumble algos and rake in millions man you have a knack for it already. I'd subscribe to that for a dollar!

1 · Reply

YGLD Dec. 22 at 4:55 AM

What An EVENTFUL Weekend This Legit Was A Loooong Weekend 🫨 • We Robbed Venezuela For 3 Oil Tankers • Redacted Epstein Files • The Bears Won • Andrew Tate Was Humbled • Jake Paul Finally Got His Ass Kicked By A Real Fighter • TPUSA Rally • Jalen Brunson Dropped Damn Near 50 • Anthony Edwards Buzzer Beater $AMCI $ATHE $WTI $LAZR $SPY

4 · Reply

YGLD Dec. 22 at 4:00 AM

So Annoying When People Ask Me Why I’m Not Trading On Certain Days 🙄 $AMCI $ATHE $AZI $LAZR $PCSA

1 · Reply

Market Cap	31.21M
Revenue (ttm)	0.00
Net Income (ttm)	-7.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,977
Avg Vol	15,254
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	65%
Beta	0.06
Analysts	Strong Sell
Price Target	$11.00